nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylnaltrexone—Gastrointestinal perforation—Docetaxel—skin cancer	0.0592	0.0592	CcSEcCtD
Methylnaltrexone—Stinging—Imiquimod—skin cancer	0.0478	0.0478	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.0272	0.0272	CcSEcCtD
Methylnaltrexone—Stinging—Fluorouracil—skin cancer	0.0264	0.0264	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vismodegib—skin cancer	0.0257	0.0257	CcSEcCtD
Methylnaltrexone—Skin disorder—Vismodegib—skin cancer	0.0255	0.0255	CcSEcCtD
Methylnaltrexone—Redness—Docetaxel—skin cancer	0.0229	0.0229	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vismodegib—skin cancer	0.0227	0.0227	CcSEcCtD
Methylnaltrexone—Pain—Vismodegib—skin cancer	0.0224	0.0224	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Vismodegib—skin cancer	0.0215	0.0215	CcSEcCtD
Methylnaltrexone—Abdominal pain—Vismodegib—skin cancer	0.0207	0.0207	CcSEcCtD
Methylnaltrexone—Erythema—Vemurafenib—skin cancer	0.0199	0.0199	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vismodegib—skin cancer	0.018	0.018	CcSEcCtD
Methylnaltrexone—Erythema—Imiquimod—skin cancer	0.0169	0.0169	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.0168	0.0168	CcSEcCtD
Methylnaltrexone—Vomiting—Vismodegib—skin cancer	0.0167	0.0167	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Vemurafenib—skin cancer	0.0159	0.0159	CcSEcCtD
Methylnaltrexone—Skin disorder—Vemurafenib—skin cancer	0.0157	0.0157	CcSEcCtD
Methylnaltrexone—Nausea—Vismodegib—skin cancer	0.0156	0.0156	CcSEcCtD
Methylnaltrexone—Injection site reaction—Docetaxel—skin cancer	0.0154	0.0154	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.0143	0.0143	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Vemurafenib—skin cancer	0.014	0.014	CcSEcCtD
Methylnaltrexone—Oedema—Imiquimod—skin cancer	0.0138	0.0138	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Imiquimod—skin cancer	0.0136	0.0136	CcSEcCtD
Methylnaltrexone—Skin disorder—Imiquimod—skin cancer	0.0134	0.0134	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Imiquimod—skin cancer	0.0134	0.0134	CcSEcCtD
Methylnaltrexone—Erythema—Bleomycin—skin cancer	0.012	0.012	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Imiquimod—skin cancer	0.0119	0.0119	CcSEcCtD
Methylnaltrexone—Pain—Imiquimod—skin cancer	0.0118	0.0118	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Imiquimod—skin cancer	0.0113	0.0113	CcSEcCtD
Methylnaltrexone—Erythema—Dactinomycin—skin cancer	0.0112	0.0112	CcSEcCtD
Methylnaltrexone—Diarrhoea—Vemurafenib—skin cancer	0.0111	0.0111	CcSEcCtD
Methylnaltrexone—Abdominal pain—Imiquimod—skin cancer	0.0109	0.0109	CcSEcCtD
Methylnaltrexone—Dizziness—Vemurafenib—skin cancer	0.0107	0.0107	CcSEcCtD
Methylnaltrexone—Vomiting—Vemurafenib—skin cancer	0.0103	0.0103	CcSEcCtD
Methylnaltrexone—Erythema—Temozolomide—skin cancer	0.0102	0.0102	CcSEcCtD
Methylnaltrexone—Oedema—Bleomycin—skin cancer	0.00982	0.00982	CcSEcCtD
Methylnaltrexone—Nausea—Vemurafenib—skin cancer	0.00963	0.00963	CcSEcCtD
Methylnaltrexone—Diarrhoea—Imiquimod—skin cancer	0.00946	0.00946	CcSEcCtD
Methylnaltrexone—Erythema—Fluorouracil—skin cancer	0.00935	0.00935	CcSEcCtD
Methylnaltrexone—Oedema—Dactinomycin—skin cancer	0.00916	0.00916	CcSEcCtD
Methylnaltrexone—Dizziness—Imiquimod—skin cancer	0.00914	0.00914	CcSEcCtD
Methylnaltrexone—Vomiting—Imiquimod—skin cancer	0.00879	0.00879	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.00858	0.00858	CcSEcCtD
Methylnaltrexone—Pain—Bleomycin—skin cancer	0.0084	0.0084	CcSEcCtD
Methylnaltrexone—Oedema—Temozolomide—skin cancer	0.00828	0.00828	CcSEcCtD
Methylnaltrexone—Nausea—Imiquimod—skin cancer	0.00821	0.00821	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Temozolomide—skin cancer	0.00812	0.00812	CcSEcCtD
Methylnaltrexone—Skin disorder—Temozolomide—skin cancer	0.00805	0.00805	CcSEcCtD
Methylnaltrexone—Hyperhidrosis—Temozolomide—skin cancer	0.00801	0.00801	CcSEcCtD
Methylnaltrexone—Pain—Dactinomycin—skin cancer	0.00783	0.00783	CcSEcCtD
Methylnaltrexone—Oedema—Fluorouracil—skin cancer	0.00763	0.00763	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Dactinomycin—skin cancer	0.00749	0.00749	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Fluorouracil—skin cancer	0.00749	0.00749	CcSEcCtD
Methylnaltrexone—Abdominal pain—Dactinomycin—skin cancer	0.00724	0.00724	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Temozolomide—skin cancer	0.00715	0.00715	CcSEcCtD
Methylnaltrexone—Pain—Temozolomide—skin cancer	0.00708	0.00708	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Temozolomide—skin cancer	0.00677	0.00677	CcSEcCtD
Methylnaltrexone—Erythema—Docetaxel—skin cancer	0.00675	0.00675	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00659	0.00659	CcSEcCtD
Methylnaltrexone—Abdominal pain—Temozolomide—skin cancer	0.00655	0.00655	CcSEcCtD
Methylnaltrexone—Pain—Fluorouracil—skin cancer	0.00653	0.00653	CcSEcCtD
Methylnaltrexone—Diarrhoea—Dactinomycin—skin cancer	0.00627	0.00627	CcSEcCtD
Methylnaltrexone—Vomiting—Bleomycin—skin cancer	0.00624	0.00624	CcSEcCtD
Methylnaltrexone—Nausea—Bleomycin—skin cancer	0.00583	0.00583	CcSEcCtD
Methylnaltrexone—Vomiting—Dactinomycin—skin cancer	0.00582	0.00582	CcSEcCtD
Methylnaltrexone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.00571	0.00571	CcSEcCtD
Methylnaltrexone—Diarrhoea—Temozolomide—skin cancer	0.00567	0.00567	CcSEcCtD
Methylnaltrexone—Oedema—Docetaxel—skin cancer	0.00551	0.00551	CcSEcCtD
Methylnaltrexone—Dizziness—Temozolomide—skin cancer	0.00548	0.00548	CcSEcCtD
Methylnaltrexone—Nausea—Dactinomycin—skin cancer	0.00544	0.00544	CcSEcCtD
Methylnaltrexone—Nervous system disorder—Docetaxel—skin cancer	0.0054	0.0054	CcSEcCtD
Methylnaltrexone—Skin disorder—Docetaxel—skin cancer	0.00535	0.00535	CcSEcCtD
Methylnaltrexone—Vomiting—Temozolomide—skin cancer	0.00527	0.00527	CcSEcCtD
Methylnaltrexone—Diarrhoea—Fluorouracil—skin cancer	0.00522	0.00522	CcSEcCtD
Methylnaltrexone—Dizziness—Fluorouracil—skin cancer	0.00505	0.00505	CcSEcCtD
Methylnaltrexone—Nausea—Temozolomide—skin cancer	0.00492	0.00492	CcSEcCtD
Methylnaltrexone—Vomiting—Fluorouracil—skin cancer	0.00485	0.00485	CcSEcCtD
Methylnaltrexone—Gastrointestinal disorder—Docetaxel—skin cancer	0.00476	0.00476	CcSEcCtD
Methylnaltrexone—Pain—Docetaxel—skin cancer	0.00471	0.00471	CcSEcCtD
Methylnaltrexone—Nausea—Fluorouracil—skin cancer	0.00453	0.00453	CcSEcCtD
Methylnaltrexone—Gastrointestinal pain—Docetaxel—skin cancer	0.00451	0.00451	CcSEcCtD
Methylnaltrexone—Abdominal pain—Docetaxel—skin cancer	0.00436	0.00436	CcSEcCtD
Methylnaltrexone—Diarrhoea—Docetaxel—skin cancer	0.00377	0.00377	CcSEcCtD
Methylnaltrexone—Dizziness—Docetaxel—skin cancer	0.00364	0.00364	CcSEcCtD
Methylnaltrexone—Vomiting—Docetaxel—skin cancer	0.0035	0.0035	CcSEcCtD
Methylnaltrexone—Nausea—Docetaxel—skin cancer	0.00327	0.00327	CcSEcCtD
